a2 Milk Sees Supply Constraints Easing for Infant Formula in China

The a2 Milk Company Limited (NZX: ATM) has reported progress in resolving supply constraints that had impacted its infant formula sales in China. These issues, linked to its supplier Synlait Milk, were particularly problematic for early-stage products under its China label. During its August full-year results, the company noted that these challenges were expected to ease in the first half of the current financial year. CEO David Bortolussi confirmed during an investor call that the situation is improving but refrained from detailing supplier arrangements. This development is a positive sign for a2 Milk’s recovery in its key Chinese market.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com